Effects on the Immune System 421Nakano Y, Pross SH, Friedman H (1992) Modulation of interleukin 2 activity by delta-9-
tetrahydrocannabinol after stimulation with concanavalin A, phytohemagglutinin, or
anti-CD3 antibody. Proc Soc Exp Biol Med 201:165–168
Newell GR, Mansell PW, Wilson MB, Lynch HK, Spitz MR, Hersh EM (1985) Risk factor
analysis among men referred for possible acquired immune deficiency syndrome. Prev
Med 14:81–91
Newton C, Klein T, Friedman H (1998) The role of macrophages in THC-induced alteration
of the cytokine network. Adv Exp Med Biol 437:207–214
Newton CA, Klein TW, Friedman H (1994) Secondary immunity to Legionella pneumophila
and Th1 activity are suppressed by delta-9-tetrahydrocannabinol injection. Infect Im-
mun 62:4015–4020
Noe SN, Nyland SB, Ugen K, Friedman H, Klein TW (1998) Cannabinoid receptor agonists
enhance syncytia formation in MT-2 cells infected with cell free HIV-1MN. Adv Exp
Med Biol 437:223–229
Noe SN, Newton C, Widen R, Friedman H, Klein TW (2000) Anti-CD40, anti-CD3, and IL-2
stimulation induce contrasting changes in CB1 mRNA expression in mouse splenocytes.
J Neuroimmunol 110:161–167
Nok AJ, Ibrahim S, Arowosafe S, Longdet I, Ambrose A, Onyenekwe PC, Whong CZ (1994)
The trypanocidal effect of Cannabis sativa constituents in experimental animal try-
panosomiasis. Vet Hum Toxicol 36:522–524
Paradise LJ, Friedman H (1993) Syphilis and drugs of abuse. Adv Exp Med Biol 335:81–87
Persaud NE, Klaskala W, Tewari T, Shultz J, Baum M (1999) Drug use and syphilis. Co-factors
for HIV transmission among commercial sex workers in Guyana. West Indian Med J
48:52–56
Pross SH, Klein TW, Newton C, Smith J, Widen R, Friedman H (1990) Age-related sup-
pression of murine lymphoid cell blastogenesis by marijuana components. Dev Comp
Immunol 14:131–137
Pross SH, Nakano Y, Widen R, McHugh S, Newton CA, Klein TW, Friedman H (1992) Dif-
fering effects of delta-9-tetrahydrocannabinol (THC) on murine spleen cell populations
dependent upon stimulators. Int J Immunopharmacol 14:1019–1027
Pryce G, Ahmed Z, Hankey DJ, Jackson SJ, Croxford JL, Pocock JM, Ledent C, Petzold
A, Thompson AJ, Giovannoni G, Cuzner ML, Baker D (2003) Cannabinoids inhibit
neurodegeneration in models of multiple sclerosis. Brain 126:2191–2202
Rachelefsky GS, Opelz G (1977) Normal lymphocyte function in the presence of delta-9-
tetrahydrocannabinol. Clin Pharmacol Ther 21:44–46
Ramarathinam L, Pross S, Plescia O, Newton C, Widen R, Friedman H (1997) Differential
immunologic modulatory effects of tetrahydrocannabinol as a function of age. Mech
Ageing Dev 96:117–126
Raz A, Goldman R (1976) Effect of hashish compounds on mouse peritoneal macrophages.
Lab Invest 34:69–76
Rinaldi-Carmona M, Barth F, Millan J, Derocq JM, Casellas P, Congy C, Oustric D, Sarran M,
Bouaboula M, Calandra B, Portier M, Shire D, Brelière JC, Le Fur GL (1998) SR 144528,
the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol
Exp Ther 284:644–650
Rosenkrantz H, Miller AJ, Esber HJ (1975) Delta-9-tetrahydrocannabinol suppression of the
primary immune response in rats. J Toxicol Environ Health 1:119–125
Sacerdote P, Massi P, Panerai AE, Parolaro D (2000) In vivo and in vitro treatment with the
synthetic cannabinoid CP 55,940 decreases the in vitro migration of macrophages in the
rat: involvement of both CB1 and CB2 receptors. J Neuroimmunol 109:155–163
Schatz AR, Kessler FK, Kaminski NE (1992) Inhibition of adenylate cyclase by delta-9-
tetrahydrocannabinol in mouse spleen cells: a potential mechanism for cannabinoid-
mediated immunosuppression. Life Sci 51:L25–L30
Schatz AR, Koh WS, Kaminski NE (1993) Delta-9-tetrahydrocannabinol selectively inhibits
T-cell dependent humoral immune responses through direct inhibition of accessory
T-cell function. Immunopharmacology 26:129–137